 |
 Video: What is a Stock Split?
|
|
|
| Prothena is a biotechnology company engaged in the protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating rare neurodegenerative and peripheral amyloid diseases. Co. is developing a pipeline of therapeutic candidates for a number of indications and targets for which its ability to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins can be utilized. Co.'s wholly-owned programs include birtamimab for the treatment of AL amyloidosis, a portfolio of programs for the treatment of Alzheimer's disease including PRX012 that targets Amyloid beta and a dual Amyloid beta-Tau vaccine. According to our Prothena stock split history records, Prothena has had 0 splits. | |
|
Prothena (PRTA) has 0 splits in our Prothena stock split history database.
Looking at the Prothena stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Prothena shares, starting with a $10,000 purchase of PRTA, presented on a split-history-adjusted basis factoring in the complete Prothena stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
| Start date: |
04/22/2014 |
|
| End date: |
04/19/2024 |
|
| Start price/share: |
$33.74 |
|
| End price/share: |
$21.16 |
|
| Dividends collected/share: |
$0.00 |
|
| Total return: |
-37.29% |
|
| Average Annual Total Return: |
-4.56% |
|
| Starting investment: |
$10,000.00 |
|
| Ending investment: |
$6,270.53 |
|
| Years: |
10.00 |
|
|
|
|
|
